Candriam SCA’s Tenax Therapeutics TENX Stock Holding History

Candriam SCA’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-749,588	Closed	-$10.9M	–	693
2026 Q2	$10.9M	Buy	+749,588	New	+$9.6M	0.05%	279

Other funds holding TENX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Candriam SCA's TENX Position: Q3 2026 in Review

Candriam SCA sold out of Tenax Therapeutics (TENX) in Q3 2026, closing a stake of 749,588 shares — an estimated $10.9M sold.

Candriam SCA first reported a position in TENX in Q2 2026 and held it in 1 quarter. The position peaked at $10.9M in Q2 2026. 68 funds tracked by Wall St. Rank hold TENX as of Q3 2026.

Candriam SCA reported no remaining Tenax Therapeutics position as of Q3 2026 after selling out during the quarter.
Candriam SCA sold 749,588 Tenax Therapeutics shares in Q3 2026, an estimated $10.9M.
Candriam SCA first reported a position in Tenax Therapeutics in Q2 2026 and held it in 1 quarter.
Candriam SCA's Tenax Therapeutics position peaked at $10.9M in Q2 2026.
68 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.